ENDRA Life Sciences Q2 2024 GAAP EPS $(0.08) Misses $(0.04) Estimate
Portfolio Pulse from Benzinga Newsdesk
ENDRA Life Sciences reported a Q2 2024 GAAP EPS of $(0.08), missing the analyst consensus estimate of $(0.04) by 100%.
August 22, 2024 | 8:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
ENDRA Life Sciences reported a Q2 2024 GAAP EPS of $(0.08), missing the analyst consensus estimate of $(0.04) by 100%. This significant miss could negatively impact investor sentiment and the stock price in the short term.
The reported EPS of $(0.08) is significantly below the expected $(0.04), indicating a larger than anticipated loss. Such a miss can lead to negative investor sentiment and potential short-term decline in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100